Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price94.45 USD
Fair value86.13
Ethical score70.0/100
Our investment reviews on this name
2026-09-01Read Accumulation90.50+4.4% to today ✓
2026-08-01Read Markup74.71+26.4% to today ✓
2026-07-02Read Accumulation65.34+44.6% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Hinge Health, Inc. holds its Accumulation at $94.45. Elevated stress, defensive posture warranted, held for 15 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 15 days
Price at the screen
$94.45
Valuation
11.49 trailing · 30.89 forward price to earnings
Values screen
PASS· score 70.0
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.08%
Below 33%
Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
15.20%
Below 33%
Cash held in interest-bearing accounts and securities is 15.2% of assets, under the one-third limit.
Pass
Receivables
34.78%
Below 49%
Money owed to the company is 34.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 8.8% above the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Digital rehab platform priced well above its worth
Every time a worker strains their back on the job or an athlete needs post op rehab, the old system of clinics and physios still dominates. Hinge Health wants to automate that care through an app led platform, and the revenue line is racing ahead at 47 percent. Yet the shares trade at 87 dollars against our fair value of 77 dollars, a margin that already sits in negative territory, and the business is still posting a 79 percent negative profit margin with return on equity at minus 136 percent.
We pass for straightforward valuation reasons. Forward earnings sit on a 25.6 times multiple while the company remains deeply unprofitable, and analyst targets cluster around 80 dollars, offering little cushion. Strong revenue growth alone does not justify stretching the price when cash is still flowing out at scale and the moat remains unproven in a crowded health tech space.
Risks centre on execution and cash burn. Sustained losses at this level can quickly erode investor patience if growth slows or reimbursement contracts prove harder to win than hoped. The ethical screen is clear, yet the numbers still show a business priced for perfection it has not yet delivered. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HNGE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 21.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71.
2026-08-01Markup · changed$74.71+14.3%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71.
2026-07-18Accumulation$65.34+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71.
2026-07-03Accumulation$65.34+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$65.34Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.